156 related articles for article (PubMed ID: 2547304)
1. Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancer.
Everson LK; Jett JR; O'Fallon JR; Krook JE; Dalton RJ; Mailliard JA; Tschetter LK; Cullinan SA; Gerstner JB; Morton RF
Am J Clin Oncol; 1989 Aug; 12(4):339-44. PubMed ID: 2547304
[TBL] [Abstract][Full Text] [Related]
2. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
[TBL] [Abstract][Full Text] [Related]
3. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
[TBL] [Abstract][Full Text] [Related]
4. [Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung].
Navarro M; Mur E; Jolis L; Bellmunt J; Bodi R; Solé LA; Rubio D
Rev Clin Esp; 1991 Oct; 189(5):209-12. PubMed ID: 1666192
[TBL] [Abstract][Full Text] [Related]
5. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
Osterlind K; Hansen M; Hirsch FR; Dombernowsky P; Sörenson S; Pedersen AG; Hansen HH
Ann Oncol; 1991 Jan; 2(1):41-6. PubMed ID: 1848996
[TBL] [Abstract][Full Text] [Related]
7. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
[TBL] [Abstract][Full Text] [Related]
8. No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancer.
Eagan RT; Frytak S; Lee RE; Therneau TM; Richardson RL; Creagan ET
Am J Clin Oncol; 1987 Apr; 10(2):141-5. PubMed ID: 3031976
[TBL] [Abstract][Full Text] [Related]
9. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.
Jett JR; Everson L; Therneau TM; Krook JE; Dalton RJ; Marschke RF; Veeder MH; Brunk SF; Mailliard JA; Twito DI
J Clin Oncol; 1990 Jan; 8(1):33-8. PubMed ID: 2153193
[TBL] [Abstract][Full Text] [Related]
10. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
11. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial.
Havemann K; Wolf M; Holle R; Gropp C; Drings P; Manke HG; Hans K; Schroeder M; Heim M; Victor N
Cancer; 1987 Mar; 59(6):1072-82. PubMed ID: 3028596
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
13. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study.
Maurer LH; Pajak T; Eaton W; Comis R; Chahinian P; Faulkner C; Silberfarb PM; Henderson E; Rege VB; Baldwin PE
J Clin Oncol; 1985 Jul; 3(7):969-76. PubMed ID: 2991478
[TBL] [Abstract][Full Text] [Related]
14. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study.
Ettinger DS; Finkelstein DM; Abeloff MD; Skeel RT; Stott PB; Frontiera MS; Bonomi PD
J Natl Cancer Inst; 1992 Jul; 84(14):1077-84. PubMed ID: 1320131
[TBL] [Abstract][Full Text] [Related]
15. A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification.
Broder LE; Sridhar KS; Selawry OS; Charyulu KN; Rao RK; Saldana MJ; Donnelly EJ; Raub WA
Am J Clin Oncol; 1994 Dec; 17(6):527-37. PubMed ID: 7977175
[TBL] [Abstract][Full Text] [Related]
16. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung.
Osterlind K; Sörenson S; Hansen HH; Dombernowsky P; Hirsch FR; Hansen M; Rørth M
Cancer Res; 1983 Dec; 43(12 Pt 1):6085-9. PubMed ID: 6315227
[TBL] [Abstract][Full Text] [Related]
17. Etoposide versus methotrexate in small cell bronchial carcinoma. A randomized study of two types of four-drug chemotherapy regimens.
Nõu E; Lamberg K; Brodin O
Acta Oncol; 1992; 31(8):853-60. PubMed ID: 1337833
[TBL] [Abstract][Full Text] [Related]
18. The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.
Evans WK; Feld R; Murray N; Pater J; Shelley W; Willan A; Osoba D; Levitt M; Coy P; Hodson I
Semin Oncol; 1986 Sep; 13(3 Suppl 3):10-6. PubMed ID: 3020692
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group.
Ettinger DS; Finkelstein DM; Abeloff MD; Ruckdeschel JC; Aisner SC; Eggleston JC
J Clin Oncol; 1990 Feb; 8(2):230-40. PubMed ID: 2153765
[TBL] [Abstract][Full Text] [Related]
20. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
